This study aims to uncover the roles of ARGs in regulating chemoresistance and immunotherapy in triple-negative breast cancer (TNBC), and attempts to construct a ARGs-based multi-gene risk model, and to make a drug sensitivity prediction tool. This evidence concerns the gene SERPINA2 and triple-negative breast carcinoma.